Department of Neurology, Danish Headache Center, Copenhagen University Hospital, Rigshospitalet, Denmark.
Department of Clinical Immunology, Centre of Diagnostic Investigation, Rigshospitalet, Denmark.
Sci Rep. 2022 May 19;12(1):8487. doi: 10.1038/s41598-022-12545-2.
The real-world use of triptans in the treatment of migraine is disappointing. Only 12% of the Danish migraine population purchased a triptan between 2014 and 2019, and only 43% repurchased a triptan after first prescription. The aim of the present study was to assess whether physicians and patients adhere to the therapeutic guideline on acute migraine treatment. We interviewed 299 triptan experienced participants with migraine and 101 triptan naïve participants with migraine from the Danish Migraine Population Cohort, using a semi-structured questionnaire. Descriptive statistical analyses were used to study the association with triptan use and the assessed factors. Among triptan naïve participants with migraine, 64% had consulted their general practitioner about their migraine, of whom only 23% received information about the possibility of triptan treatment. Among triptan experienced participants, 77% had only tried one type of triptan. Only 12% could recall they had been informed by their general practitioner to try each triptan three times before giving up. Twenty percent were informed to try three different triptans in total, if the first did not work. In disagreement with the guideline, participants who reported a low pain reduction by a triptan had only tried one type of triptan. Our study shows a low adherence to therapeutic guideline for the attack treatment of migraine. There is a need for better education of general practitioners regarding treatment of migraine. Future campaigns should aim to inform both the public and the general practitioner about antimigraine treatments.
曲坦类药物在偏头痛治疗中的实际应用令人失望。2014 年至 2019 年期间，只有 12%的丹麦偏头痛患者购买了曲坦类药物，且首次处方后只有 43%的患者再次购买了曲坦类药物。本研究旨在评估医生和患者是否遵循急性偏头痛治疗的治疗指南。我们对半结构问卷采访了 299 名有曲坦类药物使用经验的偏头痛患者和 101 名有曲坦类药物使用经验的偏头痛患者，使用半结构问卷。采用描述性统计分析来研究与曲坦类药物使用和评估因素的关联。在有曲坦类药物使用经验的偏头痛患者中，64%曾就偏头痛咨询过全科医生，但只有 23%的人获得了关于曲坦类药物治疗可能性的信息。在有曲坦类药物使用经验的偏头痛患者中，77%的人只尝试过一种类型的曲坦类药物。只有 12%的人能回忆起他们曾被全科医生告知在放弃之前要尝试每种曲坦类药物三次。20%的人被告知如果第一种药物无效，总共要尝试三种不同的曲坦类药物。与指南不符的是，报告曲坦类药物缓解疼痛效果低的患者只尝试过一种类型的曲坦类药物。我们的研究表明，偏头痛发作治疗的治疗指南遵循率较低。需要对全科医生进行更好的偏头痛治疗教育。未来的宣传活动应旨在向公众和全科医生宣传偏头痛治疗方法。
